Our Leadership

Robert Mashal

Robert Mashal

Joined Sanofi Genzyme: 2016

Robert Mashal is responsible for developing the overall strategy for the oncology and I&I (immunology and inflammation) franchises in collaboration with the leadership in research, development, and the GBU.

Prior experience

  • CEO, NKT Therapeutics
  • CEO, Alinea Pharmaceuticals
  • Partner, Boston Millennia Partners (BOD member Glycofi, Cardiomems, Novalar, Sapphire, CoApt Systems)
  • Program Executive, Vertex Pharmaceuticals
  • Consultant, McKinsey & Co.

Education

  • Johns Hopkins University
  • Johns Hopkins University, Economics/Natural Sciences

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies.
OK